The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
A decade of immune-checkpoint inhibitors in cancer therapy
Open accessAbstract
Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ICIs are cancer immunotherapies that boost anti-cancer immune responses by targeting immunologic receptors on the surface of T-lymphocytes (Table 1) [13].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Self-citationSafety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,000
Pentimalli, T. M., Schallenberg, S., León-Periñán, D., Legnini, I., Theurillat, I., Thomas, G., Boltengagen, A., Fritzsche, S., Nimo, J., Ruff, L., et al. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101261 · Cited by 36
Kewan, T. Z., Ko, T., Flores, M., Sallam, Y., Haddad, A. S., & Daw, H. A. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13598 · Cited by 34
Nasillo, V., Riva, G., Paolini, A., Forghieri, F., Roncati, L., Lusenti, B., Maccaferri, M., Messerotti, A., Pioli, V., Gilioli, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041906 · Cited by 36
Bongiovanni, A., Maiorano, B. A., Azzali, I., Liverani, C., Bocchini, M., Fausti, V., Menna, G. D., Grassi, I., Sansovini, M., Riva, N., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14050476 · Cited by 34
Matsukane, R., Watanabe, H. A., Hata, K., Suetsugu, K., Tsuji, T., Egashira, N., Nakanishi, Y., Okamoto, I., & Ieiri, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-94336-9 · Cited by 34
Jungles, K. M., Holcomb, E. A., Pearson, A. N., Jungles, K. R., Bishop, C. R., Pierce, L. J., Green, M. D., & Speers, C. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022542 · Cited by 36
Huang, X., Zhong, Y., Li, Y., Zhou, X. Y., Yang, L., Zhao, B., Zhou, J., Qiao, H., Huang, D., Qian, H., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c10098 · Cited by 33
Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes
Clubb, J. D., Gao, T. A., & Chen, Y. Y. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1491 · Cited by 35
Hoffmann, E., Gerwing, M., Niland, S., Niehoff, R., Masthoff, M., Geyer, C., Wachsmuth, L., Wilken, E., Höltke, C., Heindel, W. L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006092 · Cited by 31
Byun, J., Wu, Y., Lee, J., Kim, J. S., Shim, G., & Oh, Y. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122162 · Cited by 33
Muquith, M., Espinoza, M., Elliott, A., Xiu, J., Seeber, A., El‐Deiry, W. S., Antonarakis, E. S., Graff, S. L., Hall, M. J., Borghaei, H., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00752-x · Cited by 36
Imaging 3D cell cultures with optical microscopy
Hsieh, H.-C., Han, Q., Brenes, D., Bishop, K. W., Wang, R., Wang, Y., Poudel, C., Glaser, A. K., Freedman, B., Vaughan, J. C., et al. (2025) · Nature Methods · doi:10.1038/s41592-025-02647-w · Cited by 38
Saleem, N., Wang, J., Rejuso, A., Teixeira-Pinto, A. M., Stephens, J. H., Wilson, A. M., Kieu, A., Gately, R., Boroumand, F., Chung, E. Y. M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2374 · Cited by 34
Overcoming biological barriers to improve solid tumor immunotherapy
Ukidve, A., Cu, K., Kumbhojkar, N., Lahann, J., & Mitragotri, S. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00923-8 · Cited by 33
Wang, Z., Xu, F., Hu, J., Zhang, H., Cui, L., Lu, W., He, W., Wang, X., Li, M., Zhang, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002155 · Cited by 33
Breast Cancer Predisposition Genes and Synthetic Lethality
Neiger, H. E., Siegler, E. L., & Shi, Y. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115614 · Cited by 33
Current cancer therapies and their influence on glucose control
Yim, C., Mansell, K. D., Hussein, N., & Arnason, T. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.1010 · Cited by 34
Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances
Charneau, J., Suzuki, T., Shimomura, M., Fujinami, N., & Nakatsura, T. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s291558 · Cited by 35
Plaçais, L., Dalle, S., Dereure, O., Trabelsi, S., Dalac, S., Legoupil, D., Montaudié, H., Arnault, J., Quatrebarbes, J. D., Saïag, P., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222186 · Cited by 36
Zheng, H., Wang, G., Liu, M., & Cheng, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1168226 · Cited by 32
Immune checkpoint inhibitors and acute kidney injury
Zhou, P., Gao, Y., Kong, Z., Wang, J., Si, S., Han, W., Li, J., Lv, Z., & Wang, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1353339 · Cited by 33
Chen, D., Le, S. B., Ghiaseddin, A. P., Manektalia, H., Li, M., O’Dell, A., Rahman, M., & Tran, D. D. (2025) · Med · doi:10.1016/j.medj.2025.100708 · Cited by 33
Kim, H. I., Lim, J., & Shim, J. H. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03727-y · Cited by 32
Bayless, N. L., Bluestone, J. A., Bucktrout, S. L., Butterfield, L. H., Jaffee, E. M., Koch, C. A., Roep, B. O., Sharpe, A. H., Murphy, W. J., Villani, A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002627 · Cited by 32
CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
Freile, J. Á., Avtenyuk, N. U., Corrales, M. G., Lourens, H. J., Huls, G. A., van Meerten, T., Cendrowicz, E., & Bremer, E. (2022) · Biomedicines · doi:10.3390/biomedicines10051175 · Cited by 32
Immunotherapy approaches for hematological cancers
Lanier, O. L., Pérez‐Herrero, E., Andrea, A. P. D. ’., Bahrami, K., Lee, E. Y. P., Ward, D. M., Ayala-Suárez, N., Rodríguez-Méndez, S. M., & Peppas, N. A. (2022) · iScience · doi:10.1016/j.isci.2022.105326 · Cited by 36
Sun, R., Lerousseau, M., Briend-Diop, J., Routier, É., Roy, S., Henry, T., Ka, K., Jiang, R., Temar, N., Carré, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004867 · Cited by 32
Self-citationGuo, Q., Malloy, M. W., Roweth, H. G., McAllister, S. S., Italiano, J. E., & Battinelli, E. M. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006120 · Cited by 31
Application of injectable hydrogels in cancer immunotherapy
Liu, C., Liao, Y., Liu, L., Xie, L., Liu, J., Zhang, Y., & Li, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1121887 · Cited by 33
Ganesh, S., Kim, M. J., Lee, J., Feng, X., Ule, K., Mahan, A. L., Krishnan, H. S., Wang, Z., Anzahaee, M. Y., Singhal, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.035 · Cited by 31
Song, D., Hou, S., Ma, N., Yan, B., & Gao, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1485303 · Cited by 33
Emerging Trends for Radio-Immunotherapy in Rectal Cancer
Corrò, C., Dutoit, V., & Koessler, T. (2021) · Cancers · doi:10.3390/cancers13061374 · Cited by 33
A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy
Xu, B., Lu, M., Yan, L., Ge, M., Ren, Y., Wang, R., Shu, Y., Hou, L., & Guo, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.796647 · Cited by 31
Sodji, Q. H., Nambiar, D. K., Viswanathan, V., von Eyben, R., Colburg, D. R. C., Binkley, M. S., Li, C. G., Olcina, M. M., Chang, D. T., Le, Q., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0069 · Cited by 31
Xie, F., Tang, S., Zhang, Y., Zhao, Y., Lin, Y., Yao, Y., Wang, M., Gu, Z., & Wan, J. (2024) · ACS Nano · doi:10.1021/acsnano.3c09968 · Cited by 30
CD74 as a prognostic and M1 macrophage infiltration marker in a comprehensive pan-cancer analysis
Li, R. Q., Yan, L., Zhang, L., Zhao, Y., & Lian, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-58899-7 · Cited by 36
Malik, S., Sureka, N., Ahuja, S., Aden, D., Zaheer, S., & Zaheer, S. (2024) · Cell Biology International · doi:10.1002/cbin.12226 · Cited by 32
Franzese, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312848 · Cited by 29
Müller, M. D., Holst, P. J., & Nielsen, K. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031330 · Cited by 34
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies
Belli, C., Antonarelli, G., Repetto, M., Bielo, L. B., Crimini, E., & Curigliano, G. (2022) · Cancers · doi:10.3390/cancers14174278 · Cited by 31
Ullur, A. R., Côté, G., Pelletier, K., & Kitchlu, A. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad014 · Cited by 30
Mast Cells and Resistance to Immunotherapy in Cancer
Ribatti, D. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00676-x · Cited by 31
Samarkhazan, H. S., Shafiei, F. S., Taghinejad, Z., Maleknia, M., Noormohamadi, H., Raoufi, A., & Nouri, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01795-9 · Cited by 30
Hernàndez, A. P., Clemente, M. B., Escribano, D., Calvo, R. V., García, B. N., Domínguez, J. F. O., Salas, C., García, M. M., Segovia, J., & Domínguez, F. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-21-147 · Cited by 29
Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
Vivarelli, S., Falzone, L., Leonardi, G. C., Salmeri, M., & Libra, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5255 · Cited by 29
Wanderley, C. W. S., Maganin, A. G. M., Adjafre, B., Mendes, A. S., Silva, C. E. A., de Quadros, A. U., Luiz, J. P. M., Silva, C. M. S., da Silva, N. R., de Oliveira, F. F. B., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0003 · Cited by 32
Martins, C. P., Rasbach, E., Heppt, M. V., Singh, P. K., Kulcsár, Z., Holzgruber, J., Chakraborty, A., Mucciarone, K., Kleffel, S., Brandenburg, A., et al. (2024) · Science Advances · doi:10.1126/sciadv.adi2012 · Cited by 29
Yang, Y. A., Qi, J., Hu, J., Zhou, Y., Zheng, J., Deng, W., Inam, M., Guo, J., Xie, Y., Li, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216765 · Cited by 28
Hickey, J. W., Agmon, E., Horowitz, N. B., Tan, T.-K., Lamore, M., Sunwoo, J. B., Covert, M. W., & Nolan, G. P. (2024) · Cell Systems · doi:10.1016/j.cels.2024.03.004 · Cited by 32
DNA Nanostructures: Advancing Cancer Immunotherapy
Chen, Q., Liu, Y., Chen, Q., Li, M., Xu, L., Lin, B., Tan, Y., & Liu, Z. (2024) · Small · doi:10.1002/smll.202405231 · Cited by 27
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives
Persico, P., Lorenzi, E., Dipasquale, A., Pessina, F., Navarria, P., Politi, L. S., Santoro, A., & Simonelli, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071367 · Cited by 33
Konstantinopoulos, P. A., & Cannistra, S. A. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00571 · Cited by 28
The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
Fiste, O., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Liontos, M., Koutsoukos, K., Dimopoulos, M. A., & Zagouri, F. (2021) · Vaccines · doi:10.3390/vaccines9050422 · Cited by 27
Faron, A., Opheys, N. S., Nowak, S., Sprinkart, A. M., Isaak, A., Theis, M., Mesropyan, N., Endler, C., Sirokay, J. D., Pieper, C. C., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11122314 · Cited by 29
Development of Potent Immune Modulators Targeting Stimulator of Interferon Genes Receptor
Jeon, M. J., Lee, H., Lee, J., Baek, S. Y., Lee, D.-H., Jo, S., Lee, J., Kang, M., Jung, H. R., Han, S. B., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01795 · Cited by 30
Immune checkpoint molecules in neuroblastoma: A clinical perspective
Pathania, A. S., Prathipati, P., Murakonda, S. P., Murakonda, A. B., Srivastava, A., Avadhesh, A., Byrareddy, S. N., Coulter, D. W., Gupta, S. C., & Challagundla, K. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.013 · Cited by 28
Guo, M., Vanderwalde, A. M., Yu, X., Vidal, G. A., & Tian, G. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.015 · Cited by 31
Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence
Okobi, T., Uhomoibhi, T. O., Akahara, D. E., Odoma, V. A., Sanusi, I. A., Okobi, O. E., Umana, I. P., Okobi, E. K., Okonkwo, C. C., & Harry, N. M. (2023) · Cureus · doi:10.7759/cureus.40031 · Cited by 28
Meybodi, S. M., Far, B. F., Pourmolaei, A., Baradarbarjastehbaf, F., Safaei, M., Mohammadkhani, N., & Samadani, A. A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02114-6 · Cited by 28
Qian, Y., Wang, M., Xie, Y., Sun, Q., Gao, M., & Li, C. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301728 · Cited by 28
Muraro, E., Romanò, R., Fanetti, G., Vaccher, E., Turturici, I., Lupato, V., Torre, F. B. L., Polesel, J., Fratta, E., Giacomarra, V., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103707 · Cited by 27
Dummer, R., Corrie, P. G., Gutzmer, R., Meniawy, T. M., Vecchio, M. D., Lebbé, C., Guida, M., Dutriaux, C., Dréno, B., Meyer, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02199 · Cited by 27
Hwang, S. W., Kim, M. K., & Kweon, M. (2023) · Intestinal Research · doi:10.5217/ir.2023.00019 · Cited by 28
General features, pathogenesis, and laboratory diagnostics of autoimmune encephalitis
Masciocchi, S., Businaro, P., Scaranzin, S., Morandi, C., Franciotta, D. M., & Gastaldi, M. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2247482 · Cited by 28
Chen, J., Ma, F., Zhang, Y., Xu, M., Xu, L., Liu, Y., Ma, R., & Shi, L. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202314203 · Cited by 28
Brem, S. S. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100859 · Cited by 32
Current advances in immunotherapy for cancer
Desai, I., Thakur, S., & Pagariya, P. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100652 · Cited by 27
Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
Sayed, R. E., Haibe, Y., Amhaz, G., Bouferraa, Y., & Shamseddine, A. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042142 · Cited by 27
Engineered platelets: Advocates for tumor immunotherapy
Wang, Y., Li, Z., Mo, F., Gu, Z., & Hu, Q. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101281 · Cited by 27
Kanda, Y., Okazaki, T., & Katakai, T. (2021) · Cancers · doi:10.3390/cancers13184616 · Cited by 30
Tagliamento, M., Bironzo, P., Curcio, H., Luca, E. D., Pignataro, D., Rapetti, S. G., Audisio, M., Bertaglia, V., Paratore, C., Bungaro, M., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103639 · Cited by 26
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors
Raverot, G., & Ilie, M. D. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101712 · Cited by 27
Vishnu, K. S., Win, T. T., Aye, S. N., & Basavaraj, A. K. (2022) · BMC Cancer · doi:10.1186/s12885-022-10225-y · Cited by 27
Steroid receptor coactivators – their role in immunity
Gilad, Y., Lonard, D. M., & O’Malley, B. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1079011 · Cited by 29
PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types
Chia, P. L., Ang, K. H., Thura, M., & Zeng, Q. (2023) · Theranostics · doi:10.7150/thno.79265 · Cited by 26
Zhu, H., Ma, K., Ruan, R., Yang, C., Yan, A., Li, J., Yu, Q., Sun, H., Liu, M., Zheng, H., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108536 · Cited by 26
Zhang, Z., Song, B., Wei, H., Liu, Y., Zhang, W., Yang, Y., & Sun, B. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101040 · Cited by 26
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach
Adhikary, S., Pathak, S., Palani, V., Acar, A., Banerjee, A., Al-Dewik, N. I. E., Essa, M. M., Mohammed, S. G. A. A., & Qoronfleh, M. W. (2024) · Biomedicines · doi:10.3390/biomedicines12010217 · Cited by 28
The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
Yadav, R., Khatkar, R., Yap, K. C.-Y., Kang, C., Lyu, J., SINGH, R. K., Mandal, S., Mohanta, A., Lam, H. Y., Okina, E., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02182-1 · Cited by 29
Personalized Nanovaccine Based on STING-Activating Nanocarrier for Robust Cancer Immunotherapy
Li, Y., Dong, Y., Shen, D., Guo, Y., Cao, Y., Zhang, K., Li, X., Zhu, R., Yi, J., Yao, X., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c11014 · Cited by 26
A human receptor occupancy assay to measure anti‐PD ‐1 binding in patients with prior anti‐PD ‐1
Junker, F., Gulati, P., Wessels, U., Seeber, S., Stubenrauch, K., Deak, L. C., Markert, C., Klein, C., Teixeira, P. C., & Kao, H. (2021) · Cytometry Part A · doi:10.1002/cyto.a.24334 · Cited by 26
Role of regulatory B cells in gastric cancer: Latest evidence and therapeutics strategies
Jing, Y., Xu, F., Liang, W., Liu, J., & Zhang, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107581 · Cited by 27
Tumor Organoid and Spheroid Models for Cervical Cancer
Kutle, I., Polten, R., Hachenberg, J., Klapdor, R., Morgan, M. A., & Schambach, A. (2023) · Cancers · doi:10.3390/cancers15092518 · Cited by 28
Bestion, E., Raymond, É., Mezouar, S., & Halfon, P. (2023) · Cells · doi:10.3390/cells12131702 · Cited by 27
Li, H., Zhang, L., Yang, F., Zhao, R., Li, X., & Li, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1218386 · Cited by 27
Ocular surface toxicities associated with modern anticancer therapies
Boucher, R. C., Haigh, O. L., Barreau, E., Champiat, S., Lambotte, O., Adam, C., Labétoulle, M., & Rousseau, A. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.10.002 · Cited by 26
Wong, A., Riley, M., Zhao, S., Zimmer, J., Viveiros, M. D., Wang, J. G., Esguerra, V. G., Li, M., Lopez, G., Kendra, K. L., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7059 · Cited by 25
Nouveau, L., Buatois, V., Cons, L., Chatel, L., Pontini, G., Pleche, N., & Ferlin, W. G. (2021) · European Journal of Immunology · doi:10.1002/eji.202149181 · Cited by 25
Spatiotemporal Omics-Refining the landscape of precision medicine
Zhang, J., Yin, J., Heng, Y., Xie, K., Chen, A., Amit, I., Bian, X.-W., & Xu, X. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac053 · Cited by 27
Frankish, J., Mukherjee, D., Romano, E., Frey, K., Schröder, M., Heinonen, K., Merz, C., Müller, M. R., Gieffers, C., Hill, O., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160116 · Cited by 25
Lakhani, N. J., Cosman, R., Banerji, U., Rasco, D. W., Tomaszewska‐Kiecana, M., Garralda, E., Kornacki, D., Li, J., Tian, C., Bourayou, N., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102254 · Cited by 25
Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment
Shi, X., Cheng, X., Jiang, A., Shi, W., Zhu, L., Mou, W., Glaviano, A., Liu, Z., Cheng, Q., Lin, A., et al. (2024) · Advanced Science · doi:10.1002/advs.202403423 · Cited by 25
Lutz, R., Poos, A. M., Solé-Boldo, L., John, L., Wagner, J., Prokoph, N., Baertsch, M. A., Vonficht, D., Palit, S., Brobeil, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adp6667 · Cited by 25
Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs
Kee, J. X., Yau, J. N. N., Muthuramalingam, R. P. K., Wang, X., Chng, W. H., Lopez‐Sanchez, A., Tay, K. K. W., Deng, L., Gibson, D., Bertrand, H. C., et al. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00041 · Cited by 29
Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review
Spagnolo, F., Boutros, A., Croce, E., Cecchi, F., Arecco, L., Tanda, E. T., Pronzato, P., & Lambertini, M. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13604 · Cited by 25
Kang, Y., Morita, S., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01230-4 · Cited by 25
Zaremba, A., Kramer, R., DeTemple, V. K., Bertram, S., Salzmann, M., Gesierich, A., Reinhardt, L., Baroudjian, B., Sachse, M., Mechtersheimer, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.765608 · Cited by 25
The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review
Stella, G. M., D’Agnano, V., Piloni, D., Saracino, L., Lettieri, S., Mariani, F., Lancia, A., Bortolotto, C., Rinaldi, P., Falanga, F., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-880 · Cited by 25
Regulation of pancreatic cancer therapy resistance by chemokines
Gautam, S. K., Basu, S., Aithal, A., Dwivedi, N. V., Gulati, M., & Jain, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.010 · Cited by 26
Spunde, K., Korotkaja, K., & Zajakina, A. (2022) · Biomedicines · doi:10.3390/biomedicines10092142 · Cited by 26
Metadata
- Authors
- Robert, C.
- Affiliations
- Institut Gustave Roussy (FR)
- Corresponding author
- Robert, Caroline
- ORCID
- Robert, Caroline
- Venue
- Nature Communications
- Published
- 2020-07-30
- Volume
- 11
- Issue
- 1
- Pages
- 3801-3801
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7393098
- OpenAlex
- W3045946240
- Cited by
- 1,608
- References
- 17
- Citations by year
- 2026: 154 · 2025: 250 · 2024: 312 · 2023: 339 · 2022: 315 · 2021: 227 · 2020: 9
- FWCI
- 80.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint inhibitors, cancer immunotherapy, treatment efficacy assessment, immunotherapy toxicity, patient-centered care
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Antibodies, Monoclonal, Humans, Immunotherapy, Neoplasms, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
